DoMore Diagnostics was established to meet the need for novel methods in precision medicine to personalize treatment for cancer patients. The company is based on prominent research from leading institutions including Oslo University Hospital, Oxford University, and University College of London.

The research project was selected as a Lighthouse project by the Norwegian Research Council to develop new diagnostic methods for cancer using artificial intelligence. The project was initially led by the late Prof. Håvard Danielsen, aiming to utilize AI technology in digital pathology to reduce over- and undertreatment in cancer.

DoMore Diagnostics is on a mission to bring AI-powered digital biomarkers closer to clinicians and patients, enabling personalized cancer treatment to improve patient outcomes while reducing health care costs.

DoMore Diagnostics has a management team including CEO Torbjørn Furuseth, CTO Sepp De Raedt, and other experts with extensive backgrounds in life sciences, technology, quality assurance, and medical research.

The company is supported by a scientific advisory board featuring internationally recognized oncology and pathology experts such as Dr. John L. Marshall, Dr. Jeanine Roodhart, Dr. Takayuki Yoshino, Dr. Frank A. Sinicrope, Prof. Marc Peeters, Prof. Marco Novelli, and Prof. Hans-Joachim Schmoll.